MARKET

RNA

RNA

Atrium Therapeutics, Inc
NASDAQ
12.16
-0.11
-0.90%
Opening 15:31 08/12 EDT
OPEN
12.27
PREV CLOSE
12.27
HIGH
12.35
LOW
12.06
VOLUME
36.16K
TURNOVER
--
52 WEEK HIGH
16.77
52 WEEK LOW
11.13
MARKET CAP
208.00M
P/E (TTM)
-4.5461
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RNA last week (0803-0807)?
Weekly Report · 2d ago
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Benzinga · 6d ago
Zillow downgraded, Global Payments upgraded: Wall Street’s top analyst calls
TipRanks · 6d ago
Atrium Therapeutics Initiated at Buy by HC Wainwright & Co.
Dow Jones · 6d ago
Atrium Therapeutics Price Target Announced at $25.00/Share by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25
Benzinga · 6d ago
Atrium Therapeutics initiated with a Buy at H.C. Wainwright
TipRanks · 6d ago
Weekly Report: what happened at RNA last week (0727-0731)?
Weekly Report · 08/03 10:33
More
About RNA
Atrium Therapeutics, Inc. is a biopharmaceutical company engaged in the delivery of ribonucleic acid (RNA) therapeutics for people living with cardiomyopathy. Its technology leverages the targeted RNA delivery platform, which combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with oligonucleotides. It is designed to allow selective targeting of the underlying genetic drivers of disease. Its development pipeline consists of programs that target genetically validated drivers of cardiomyopathy, which include Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2 (PRKAG2) and Phospholamban (PLN). Its genetic drivers are associated with PRKAG2 syndrome and PLN cardiomyopathy, which is a genetic heart condition associated with life-threatening forms of heart disease. Its programs are supported by preclinical data, in addition to positive clinical data generated in neuromuscular indications using the same RNA delivery platform technology.

Webull offers Atrium Therapeutics Inc stock information, including NASDAQ: RNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNA stock methods without spending real money on the virtual paper trading platform.